

Electronic Acknowledgement Receipt

| | |
|---|--|
| EFS ID: | 6472877 |
| Application Number: | 10590672 |
| International Application Number: | |
| Confirmation Number: | 2840 |
| Title of Invention: | Methods for Inhibiting Tumor Cell Growth |
| First Named Inventor/Applicant Name: | Andrew Kung |
| Correspondence Address: | Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky and Popeo One Financial Center - Boston MA 02111 US - - |
| Filer: | Cynthia A. Kozakiewicz/Donna Doyle |
| Filer Authorized By: | Cynthia A. Kozakiewicz |
| Attorney Docket Number: | 20363-025 NATL |
| Receipt Date: | 17-NOV-2009 |
| Filing Date: | 23-OCT-2007 |
| Time Stamp: | 18:45:02 |
| Application Type: | U.S. National Stage under 35 USC 371 |

Payment information:

| | |
|--|-------------|
| Submitted with Payment | yes |
| Payment Type | Credit Card |
| Payment was successfully received in RAM | \$180 |

| RAM confirmation Number | | 5819 | | | |
|---|---|--|--|------------------|------------------|
| Deposit Account | | | | | |
| Authorized User | | | | | |
| File Listing: | | | | | |
| Document Number | Document Description | File Name | File Size(Bytes)/ Message Digest | Multi Part /.zip | Pages (if appl.) |
| 1 | Transmittal Letter | 20363_025NATL_Transmittal.pdf | 78272 | no | 1 |
| | | | a6f01cc47c7917333c411bb9e87262cb0a887529 | | |
| Warnings: | | | | | |
| Information: | | | | | |
| 2 | Transmittal Letter | 20363_025NATL_SIDS.pdf | 90196 | no | 2 |
| | | | fe554742c4c924d8cd3814aa7eff72e857cfa5 | | |
| Warnings: | | | | | |
| Information: | | | | | |
| 3 | Information Disclosure Statement (IDS) Filed (SB/08) | 20363_025NATL_1449.pdf | 200367 | no | 4 |
| | | | 840b4ff4473f186260016593a8b0979e0b13b9e9 | | |
| Warnings: | | | | | |
| Information: | | | | | |
| This is not an USPTO supplied IDS fillable form | | | | | |
| 4 | NPL Documents | Arcaro.pdf | 44724 | no | 2 |
| | | | 5ff443f9c2f5d2547bb47cf7477ba9f6f2bb7e7 | | |
| Warnings: | | | | | |
| Information: | | | | | |
| 5 | NPL Documents | Capraro_Synthesis.pdf | 127273 | no | 1 |
| | | | 61d86d59adf870e28b371d6bb84dddb0923a9dce | | |
| Warnings: | | | | | |
| Information: | | | | | |
| 6 | NPL Documents | Ferreira_Brandao_Guerreiro.pdf | 59024 | no | 1 |
| | | | da5ca7e79a8e8034cb8abb325b554cf727219012 | | |
| Warnings: | | | | | |
| Information: | | | | | |
| 7 | NPL Documents | Garcia_Echeverria_Discovery_Potent.pdf | 63117 | no | 1 |
| | | | 064e70c223f30f93d35461badb6c37f5874d57f1 | | |
| Warnings: | | | | | |
| Information: | | | | | |

| | | | | | |
|--------------|---------------|--|---|----|---|
| 8 | NPL Documents | Garcia_Echeverria_Targeted_Anti_Cancer.pdf | 136666 21d47c5674758dfea7739931bbc2bf1cdc4de343 | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |
| 9 | NPL Documents | Garcia_Echeverria_In_Vivo_Cancer_Cell.pdf | 205497 aec2473a42200dc930eed636e65194eedcf75c | no | 9 |
| Warnings: | | | | | |
| Information: | | | | | |
| 10 | NPL Documents | Garcia_Echeverria_NVP_AEW541_Novel_TargetedI.pdf | 112128 56744d6ec3610895876d405a2e87e3079903c3c9 | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 11 | NPL Documents | Krystal_IGF-1R.pdf | 211269 5d0b1335abc9eea839865e8eb0b5751508ee08c8 | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 12 | NPL Documents | Krystal_small_molecule.pdf | 306764 8d61e7885f72dfed6fc13aa8612031b40593452d | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |
| 13 | NPL Documents | Mitsiades1.pdf | 295968 c0352bf6c3f1ae44be58726ce94104edae91aa20 | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |
| 14 | NPL Documents | Mitsiades2.pdf | 164876 25769e5afba861936f21128be045fda5520a462d | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 15 | NPL Documents | Mitsides3.pdf | 374727 f010dbcb5b742c2e7f5d4f7ab31c68a2b7f313542 | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |
| 16 | NPL Documents | OReilly_Abrogation_EurJCancer.pdf | 150557 6a8457f5d87f6173f4f68a102e633f50bbde4751 | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |

| | | | | | |
|--------------|-------------------------|---|---|----|---|
| 17 | NPL Documents | Schnell_Characterization.pdf | 259935 0c6d71633e9a2da5378553f57f3cc78fffb3c1f | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |
| 18 | NPL Documents | Scotlandi_Effectiveness_EurJCan- cer.pdf | 149400 8b341486142a01543b7430bc2c95e45e91f812dc | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 19 | NPL Documents | Warshamana_Greene_Insulin_I- ike.pdf | 1911610 e17d08ccee66639b283efa7c4fec8fcf804640b5 | no | 9 |
| Warnings: | | | | | |
| Information: | | | | | |
| 20 | NPL Documents | Warshamana_Greene_Novel_I- GF-1R.pdf | 257795 e5c0e61ce843d16cacb26f928ca4a7d596d1b3fa | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |
| 21 | NPL Documents | Warshamana_Greene_Mol_Can- cer.pdf | 409126 5d64c3df78f90d31e178dd3e9c3c3b7c1553da49 | no | 9 |
| Warnings: | | | | | |
| Information: | | | | | |
| 22 | NPL Documents | Zhao_IGF_1_EurJCancer.pdf | 147279 8fee01b5132e9a5a0eaa318af7aaec112052b1fb | no | 1 |
| Warnings: | | | | | |
| Information: | | | | | |
| 23 | NPL Documents | Inhibitors.pdf | 294480 7c51f736ecd2dbe84f0e655944d61172bc71ce0e | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |
| 24 | NPL Documents | Mitsiades4.pdf | 94307 4f5a724b40cf23c6b5f246210919d49e43821ce9 | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |
| 25 | Fee Worksheet (PTO-875) | fee-info.pdf | 30265 5065bed281a4cd32d0fc2eb06271b56a25142dc4 | no | 2 |
| Warnings: | | | | | |
| Information: | | | | | |

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.